Lonza Biologics Roadshow – Preparing for a Successful Transition to the Clinic

Lonza Bench to Clinic avoid missing milestones, rework or process failures for standard mAbs, bispecifics, bioconjugates, and new molecular formats. Have a tailored conversation with our scientists and team about your candidates’ specific needs:

• De-risking and optimizing your lead
• Manufacturability screening, protein engineering, Humanization, Assessing the potential immune response
• Immunogenicity, Immunotoxicity and potency evaluation, de-immunization Generating materials for your in vitro and preclinical studies • Non-GMP protein expression and supply
• Guaranteed antibody supply up to 2g within 6 weeks Creating cell lines and processes with future manufacturability, cost of goods and speed in mind
• Standard monoclonal, bispecific or new molecular formats – We have an approach for each
• 11 months from DNA to IND. Guaranteed!*
• Accessing a global development and manufacturing network Lonza brings it together – One place, your bioconjugate, your solution
• New Bioconjugates Early Development Service (EDS) offering
• Technology Toolbox – Solution to find your way to IND

Contact [email protected] to learn more!

Set up a Tailored Discussion with our Experts:
Alejandro Preciado, Business Development Biologics
Jaime Okray, Business Development Biologics
Yvette Stallwood, Early De-risking and Lead Optimization Head Cambridge Site and Early Development Services
Noel Smith, Head Immunology, Early Development Services Expression and Process Development
Jennifer Peuchot, Group Leader Cell Culture Development
Matthieu Settler, Head of Mammalian Development Services
Sandro Holzer, Head of Process Development
Raphael Frey Senior Scientist Bioconjugates EDS
Christoph Bernoulli, Drug Product Development Head MSAT
Claudia Müller Drug Product, Head Formulation Development

* For antibodies and antibody like molecules. From receipt of the gene sequence. Subject to terms and conditions.